Anti-Influenza Treatment: Drugs Currently Used and Under Development;Tratamiento antigripal: fármacos actualmente utilizados y nuevos agentes en desarrollo

Archivos de Bronconeumologia

Volumn 53, Issue 1, 2017, Pages 19-26

  Amarelle, Luciano ^a,b   Lecuona, Emilia ^a   Sznajder, Jacob I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

Drugs; Influenza; Influenza virus; Treatment

Indexed keywords

ANTIVIRUS AGENT; VIRAL PROTEIN; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 FLUORO 4 IODOANILINO) 1,6 DIHYDRO N (2 HYDROXYETHOXY) 1,5 DIMETHYL 6 OXONICOTINAMIDE; ACETYLSALICYLIC ACID; AMANTADINE; APROTININ; ARBIDOL; BAFILOMYCIN A1; BAICALIN; CONCANAMYCIN A; FAVIPIRAVIR; GELDANAMYCIN; GLYCYRRHIZIC ACID; LANINAMIVIR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAPROXEN; NITAZOXANIDE; OSELTAMIVIR; OUABAIN; PERAMIVIR; PIMODIVIR; RDEA 119; RIBAVIRIN; RIMANTADINE; SELUMETINIB; TANESPIMYCIN; TARIBAVIRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERDINEXOR; ZANAMIVIR;

ANTIVIRAL ACTIVITY; DRUG EFFICACY; DRUG TARGETING; GENETIC VARIABILITY; HOST CELL; HUMAN; INFLUENZA; INFLUENZA VIRUS; MORBIDITY; MORTALITY; RISK REDUCTION; SHORT SURVEY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MAPK SIGNALING; VIRAL PHENOMENA AND FUNCTIONS; RISK FACTOR; DRUG RESEARCH; DRUG RESISTANCE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS MORPHOLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; MAP KINASE SIGNALING SYSTEM; VIRAL PROTEINS; VIRUS PHYSIOLOGICAL PHENOMENA;

EID: 85026249393     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2016.11.020     Document Type: Short Survey

References (126)

1. 1 Cox, N.J., Subbarao, K., Influenza. Lancet. 354 (1999), 1277–1282.
2. 2 Van Elden, L.J., van Essen, G.A., Boucher, C.A., van Loon, A.M., Nijhuis, M., Schipper, P., et al. Clinical diagnosis of influenza virus infection: Evaluation of diagnostic tools in general practice. Br J Gen Pract. 51 (2001), 630–634.
3. 3 Cao, B., Li, X.W., Mao, Y., Wang, J., Lu, H.Z., Chen, Y.S., et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 361 (2009), 2507–2517.
4. 4 Jain, S., Kamimoto, L., Bramley, A.M., Schmitz, A.M., Benoit, S.R., Louie, J., et al. Hospitalized patients with 2009 H1N1 influenza in the United States, april-june 2009. N Engl J Med. 361 (2009), 1935–1944.
5. 5 World Health Organization. Influenza (seasonal). Fact sheet No 211, March 2014. Disponible en: www.who.int/mediacentre/factsheets/fs211/en/.
6. 6 Li, T.C., Chan, M.C., Lee, N., Clinical implications of antiviral resistance in influenza. Viruses. 7 (2015), 4929–4944.
7. 7 Fiore, A.E., Fry, A., Shay, D., Gubareva, L., Bresse, J.S., Uyeki, T.M., Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza –- Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60 (2011), 1–24 Disponible en: www.cdc.gov/mmwr/preview/mmwrhtml/rr6001a1.htm.
8. 8 Mosnier, A., Caini, S., Daviaud, I., Nauleau, E., Bui, T.T., Debost, E., et al. Clinical characteristics are similar across type A and B influenza virus infections. PLoS One., 10, 2015, e0136186.
9. 9 Joosting, A.C., Head, B., Bynoe, M.L., Tyrrell, D.A., Production of common colds in human volunteers by influenza C virus. Br Med J. 4 (1968), 153–154.
10. 10 Kauppila, J., Ronkko, E., Juvonen, R., Saukkoriipi, A., Saikku, P., Bloigu, A., et al. Influenza C virus infection in military recruits–Symptoms and clinical manifestation. J Med Virol. 86 (2014), 879–885.
11. 11 Inglis, S.C., Carroll, A.R., Lamb, R.A., Mahy, B.W., Polypeptides specified by the influenza virus genome: I. Evidence for eight distinct gene products specified by fowl plague virus. Virology. 74 (1976), 489–503.
12. 12 Compans, R.W., Klenk, H.D., Caliguiri, L.A., Choppin, P.W., Influenza virus proteins. I. Analysis of polypeptides of the virion and identification of spike glycoproteins. Virology. 42 (1970), 880–889.
13. 13 Skehel, J.J., Schild, G.C., The polypeptide composition of influenza A viruses. Virology. 44 (1971), 396–408.
14. 14 Hutchinson, E.C., Charles, P.D., Hester, S.S., Thomas, B., Trudgian, D., Martínez-Alonso, M., et al. Conserved and host-specific features of influenza virion architecture. Nat Commun., 5, 2014, 4816.
15. 15 McGeoch, D., Fellner, P., Newton, C., Influenza virus genome consists of eight distinct RNA species. Proc Natl Acad Sci U S A. 73 (1976), 3045–3049.
16. 16 Shaw, M.L., Palese, P., Orthomyxoviridae. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, 1, 2013, Lippincott Williams and Wilkins, Philadelphia, PA.
17. 17 Weis, W., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J., Wiley, D.C., Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature. 333 (1988), 426–431.
18. 18 Couceiro, J.N., Paulson, J.C., Baum, L.G., Influenza virus strains selectively recognize sialyloligosaccharides on human respiratory epithelium; the role of the host cell in selection of hemagglutinin receptor specificity. Virus Res. 29 (1993), 155–165.
19. 19 Nicholls, J.M., Bourne, A.J., Chen, H., Guan, Y., Peiris, J.S., Sialic acid receptor detection in the human respiratory tract: Evidence for widespread distribution of potential binding sites for human and avian influenza viruses. Respir Res., 8, 2007, 73.
20. 20 Böttcher, E., Matrosovich, T., Beyerle, M., Klenk, H.D., Garten, W., Matrosovich, M., Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol. 80 (2006), 9896–9898.
21. 21 Hatesuer, B., Bertram, S., Mehnert, N., Bahgat, M.M., Nelson, P.S., Pöhlmann, S., et al. Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice. PLoS Pathog., 9, 2013, e1003774.
22. 22 Skehel, J.J., Bayley, P.M., Brown, E.B., Martin, S.R., Waterfield, M.D., White, J.M., et al. Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U S A. 79 (1982), 968–972.
23. 23 White, J., Kartenbeck, J., Helenius, A., Membrane fusion activity of influenza virus. EMBO J. 1 (1982), 217–222.
24. 24 White, J., Matlin, K., Helenius, A., Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses. J Cell Biol. 89 (1981), 674–679.
25. 25 Bui, M., Whittaker, G., Helenius, A., Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol. 70 (1996), 8391–8401.
26. 26 Okada, A., Miura, T., Takeuchi, H., Zinc- and pH-dependent conformational transition in a putative interdomain linker region of the influenza virus matrix protein M1. Biochemistry. 42 (2003), 1978–1984.
27. 27 Stauffer, S., Feng, Y., Nebioglu, F., Heilig, R., Picotti, P., Helenius, A., Stepwise priming by acidic pH and a high K+ concentration is required for efficient uncoating of influenza A virus cores after penetration. J Virol. 88 (2014), 13029–13046.
28. 28 Emtage, J.S., Catlin, G.H., Carey, N.H., Polyadenylation and reverse transcription of influenza viral RNA. Nucleic Acids Res. 6 (1979), 1221–1239.
29. 29 Nayak, D.P., Hui, E.K., Barman, S., Assembly and budding of influenza virus. Virus Res. 106 (2004), 147–165.
30. 30 Matsuoka, Y., Matsumae, H., Katoh, M., Eisfeld, A.J., Neumann, G., Hase, T., et al. A comprehensive map of the influenza A virus replication cycle. BMC Syst Biol., 7, 2013, 97.
31. 31 U. S. Food and Drug Administration. Drugs [consultado 28 Abr 2016]. Disponible en: www.fda.gob/drugs.
32. 32 Centers for Disease Control and Prevention. Influenza (Flu) [consultado 28 Abr 2016]. Disponible en: http://www.cdc.gov/flu.
33. 33 Schnell, J.R., Chou, J.J., Structure and mechanism of the M2 proton channel of influenza A virus. Nature. 451 (2008), 591–595.
34. 34 Steinhauer, D.A., Wharton, S.A., Skehel, J.J., Wiley, D.C., Hay, A.J., Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: Evidence for virus-specific regulation of the pH of glycoprotein transport vesicles. Proc Natl Acad Sci U S A. 88 (1991), 11525–11529.
35. 35 Zarubaev, V.V., Golod, E.L., Anfimov, P.M., Shtro, A.A., Saraev, V.V., Gavrilov, A.S., et al. Synthesis and anti-viral activity of azolo-adamantanes against influenza A virus. Bioorg Med Chem. 18 (2010), 839–848.
36. 36 Wu, Y., Canturk, B., Jo, H., Ma, C., Gianti, E., Klein, M.L., et al. Flipping in the pore: Discovery of dual inhibitors that bind in different orientations to the wild-type versus the amantadine-resistant S31 N mutant of the influenza A virus M2 proton channel. J Am Chem Soc. 136 (2014), 17987–17995.
37. 37 Sidwell, R.W., Huffman, J.H., Barnard, D.L., Bailey, K.W., Wong, M.H., Morrison, A., et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor. Antiviral Res. 37 (1998), 107–120.
38. 38 Takashita, E., Meijer, A., Lackenby, A., Gubareva, L., Rebelo-de-Andrade, H., Besselaar, T., et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 117 (2015), 27–38.
39. 39 Kati, W.M., Montgomery, D., Carrick, R., Gubareva, L., Maring, C., McDaniel, K., et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother. 46 (2002), 1014–1021.
40. 40 Abed, Y., Nehme, B., Baz, M., Boivin, G., Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res. 77 (2008), 163–166.
41. 41 Chen, B.L., Wang, Y.J., Guo, H., Zeng, G.Y., Design, synthesis, and biological evaluation of crenatoside analogues as novel influenza neuraminidase inhibitors. Eur J Med Chem. 109 (2016), 199–205.
42. 42 El-Nezhawy, A.O., Eweas, A.F., Maghrabi, I.A., Edalo, A.S., Abdelwahab, S.F., Design, synthesis, and molecular docking of novel pyrrolooxazepinediol derivatives with anti-influenza neuraminidase activity. Arch Pharm (Weinheim). 348 (2015), 786–795.
43. 43 Jefferson, T., Jones, M., Doshi, P., Spencer, E.A., Onakpoya, I., Heneghan, C.J., Oseltamivir for influenza in adults and children: Systematic review of clinical study reports and summary of regulatory comments. BMJ., 348, 2014, g2545.
44. 44 Dobson, J., Whitley, R.J., Pocock, S., Monto, A.S., Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. Lancet. 385 (2015), 1729–1737.
45. 45 Adisasmito, W., Chan, P.K., Lee, N., Oner, A.F., Gasimov, V., Aghayev, F., et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: Analysis of a Global Patient Registry. J Infect Dis. 202 (2010), 1154–1160.
46. 46 Lee, N., Choi, K.W., Chan, P.K., Hui, D.S., Lui, G.C., Wong, B.C., et al. Outcomes of adults hospitalised with severe influenza. Thorax. 65 (2010), 510–515.
47. 47 McGeer, A., Green, K.A., Plevneshi, A., Shigayeva, A., Siddiqi, N., Raboud, J., et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 45 (2007), 1568–1575.
48. 48 PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza (2015-16). Version 6.0, September 2015 [consultado 28 Abr 2016]. Disponible en: www.gov.uk/government/uploads/system/uploads/attachment_data/file/457735/PHE_guidance_antivirals_influenza_2015_to_2016.pdf.
49. 49 World Health Organization. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. 2010, World Health Organization, Geneva.
50. 50 Basu, A., Antanasijevic, A., Wang, M., Li, B., Mills, D.M., Ames, J.A., et al. New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion. J Virol. 88 (2014), 1447–1460.
51. 51 Matsubara, T., Onishi, A., Saito, T., Shimada, A., Inoue, H., Taki, T., et al. Sialic acid-mimic peptides as hemagglutinin inhibitors for anti-influenza therapy. J Med Chem. 53 (2010), 4441–4449.
52. 52 Wu, W., Lin, D., Shen, X., Li, F., Fang, Y., Li, K., et al. New influenza A virus entry inhibitors derived from the viral fusion peptides. PLoS One., 10, 2015, e0138426.
53. 53 Teissier, E., Zandomeneghi, G., Loquet, A., Lavillette, D., Lavergne, J.P., Montserret, R., et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol. PLoS One., 6, 2011, e15874.
54. 54 Trofimov, F.A., Tsyshkova, N.G., Zotova, S.A., Grinev, A.N., Synthesis of a new antiviral agent, arbidole. Pharm Chem J 27 (1993), 75–76.
55. 55 Kiselev, O.I., Maleev, V.V., Deeva, E.G., Leneva, I.A., Sel'kova, E.P., Osipova, E.A., et al. [Clinical efficacy of arbidol (umifenovir) in the therapy of influenza in adults: Preliminary results of the multicenter double-blind randomized placebo-controlled study ARBITR] Russian. Ter Arkh. 87 (2015), 88–96.
56. 56 Leneva, I.A., Russell, R.J., Boriskin, Y.S., Hay, A.J., Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 81 (2009), 132–140.
57. 57 Brancato, V., Peduto, A., Wharton, S., Martin, S., More, V., Di Mola, A., et al. Design of inhibitors of influenza virus membrane fusion: Synthesis, structure-activity relationship and in vitro antiviral activity of a novel indole series. Antiviral Res. 99 (2013), 125–135.
58. 58 Whittle, J.R.R., Zhang, R., Khurana, S., King, L.R., Manischewitz, J., Golding, H., et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 108 (2011), 14216–14221.
59. 59 Benjamin, E., Wang, W., McAuliffe, J.M., Palmer-Hill, F.J., Kallewaard, N.L., Chen, Z., et al. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J Virol. 88 (2014), 6743–6750.
60. 60 Koday, M.T., Nelson, J., Chevalier, A., Koday, M., Kalinoski, H., Stewart, L., et al. A computationally designed hemagglutinin stem-binding protein provides in vivo protection from influenza independent of a host immune response. PLoS Pathog., 12, 2016, e1005409.
61. 61 Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 49 (2005), 981–986.
62. 62 Kiso, M., Takahashi, K., Sakai-Tagawa, Y., Shinya, K., Sakabe, S., Le, Q.M., et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci U S A. 107 (2010), 882–887.
63. 63 Smee, D.F., Hurst, B.L., Wong, M.H., Bailey, K.W., Tarbet, E.B., Morrey, J.D., et al. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother. 54 (2010), 126–133.
64. 64 Tarbet, E.B., Maekawa, M., Furuta, Y., Babu, Y.S., Morrey, J.D., Smee, D.F., Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res. 94 (2012), 103–110.
65. 65 Cianci, C., Tiley, L., Krystal, M., Differential activation of the influenza virus polymerase via template RNA binding. J Virol. 69 (1995), 3995–3999.
66. 66 Bouloy, M., Morgan, M.A., Shatkin, A.J., Krug, R.M., Cap and internal nucleotides of reovirus mRNA primers are incorporated into influenza viral complementary RNA during transcription in vitro. J Virol. 32 (1979), 895–904.
67. 67 Severin, C., Rocha de Moura, T., Liu, Y., Li, K., Zheng, X., Luo, M., The cap-binding site of influenza virus protein PB2 as a drug target. Acta Crystallogr D Struct Biol. 72:Pt 2 (2016), 245–253.
68. 68 Clark, M.P., Ledeboer, M.W., Davies, I., Byrn, R.A., Jones, S.M., Perola, E., et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 57 (2014), 6668–6678.
69. 69 Byrn, R.A., Jones, S.M., Bennett, H.B., Bral, C., Clark, M.P., Jacobs, M.D., et al. Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit. Antimicrob Agents Chemother. 59 (2015), 1569–1582.
70. 70 Portela, A., Digard, P., The influenza virus nucleoprotein: A multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol. 83:Pt 4 (2002), 723–734.
71. 71 Amorim, M.J., Kao, R.Y., Digard, P., Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection. J Virol. 87 (2013), 4694–4703.
72. 72 Cheng, H., Wan, J., Lin, M.I., Liu, Y., Lu, X., Liu, J., et al. Design, synthesis, and in vitro biological evaluation of 1H-1,2,3-triazole-4-carboxamide derivatives as new anti-influenza A agents targeting virus nucleoprotein. J Med Chem. 55 (2012), 2144–2153.
73. 73 Lejal, N., Tarus, B., Bouguyon, E., Chenavas, S., Bertho, N., Delmas, B., et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 57 (2013), 2231–2242.
74. 74 Tarus, B., Bertrand, H., Zedda, G., di Primo, C., Quideau, S., Slama-Schwok, A., Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of Influenza A virus. J Biomol Struct Dyn. 33 (2015), 1899–1912.
75. 75 Hatada, E., Fukuda, R., Binding of influenza A virus NS1 protein to dsRNA in vitro. J Gen Virol. 73:Pt 12 (1992), 3325–3329.
76. 76 Lu, Y., Wambach, M., Katze, M.G., Krug, R.M., Binding of the influenza virus NS1 protein to double-stranded RNA inhibits the activation of the protein kinase that phosphorylates the elF-2 translation initiation factor. Virology. 214 (1995), 222–228.
77. 77 Alonso-Caplen, F.V., Nemeroff, M.E., Qiu, Y., Krug, R.M., Nucleocytoplasmic transport: The influenza virus NS1 protein regulates the transport of spliced NS2 mRNA and its precursor NS1 mRNA. Genes Dev. 6 (1992), 255–267.
78. 78 Fortes, P., Beloso, A., Ortin, J., Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J. 13 (1994), 704–712.
79. 79 Qiu, Y., Krug, R.M., The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A). J Virol. 68 (1994), 2425–2432.
80. 80 García-Sastre, A., Egorov, A., Matassov, D., Brandt, S., Levy, D.E., Durbin, J.E., et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 252 (1998), 324–330.
81. 81 Gack, M.U., Albrecht, R.A., Urano, T., Inn, K.S., Huang, I.C., Carnero, E., et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe. 5 (2009), 439–449.
82. 82 Kuo, R.L., Li, L.H., Lin, S.J., Li, Z.H., Chen, G.W., Chang, C.K., et al. The role of N-terminus-truncated NS1 proteins of influenza A virus in inhibiting IRF3 activation. J Virol. 90 (2016), 4696–4705.
83. 83 Basu, D., Walkiewicz, M.P., Frieman, M., Baric, R.S., Auble, D.T., Engel, D.A., Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol. 83 (2009), 1881–1891.
84. 84 Jablonski, J.J., Basu, D., Engel, D.A., Geysen, H.M., Design, synthesis, and evaluation of novel small molecule inhibitors of the influenza virus protein NS1. Bioorg Med Chem. 20 (2012), 487–497.
85. 85 Walkiewicz, M.P., Basu, D., Jablonski, J.J., Geysen, H.M., Engel, D.A., Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner. J Gen Virol. 92:Pt 1 (2011), 60–70.
86. 86 Nayak, M.K., Agrawal, A.S., Bose, S., Naskar, S., Bhowmick, R., Chakrabarti, S., et al. Antiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses. J Antimicrob Chemother. 69 (2014), 1298–1310.
87. 87 Shapira, S.D., Gat-Viks, I., Shum, B.O., Dricot, A., de Grace, M.M., Wu, L., et al. A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell. 139 (2009), 1255–1267.
88. 88 Watanabe, T., Kawakami, E., Shoemaker, J.E., Lopes, T.J., Matsuoka, Y., Tomita, Y., et al. Influenza virus-host interactome screen as a platform for antiviral drug development. Cell Host Microbe. 16 (2014), 795–805.
89. 89 De Chassey, B., Meyniel-Schicklin, L., Aublin-Gex, A., André, P., Lotteau, V., Genetic screens for the control of influenza virus replication: From meta-analysis to drug discovery. Mol Biosyst. 8 (2012), 1297–1303.
90. 90 Moss, R.B., Hansen, C., Sanders, R.L., Hawley, S., Li, T., Steigbigel, R.T., A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection. J Infect Dis. 206 (2012), 1844–1851.
91. 91 Malakhov, M.P., Aschenbrenner, L.M., Smee, D.F., Wandersee, M.K., Sidwell, R.W., Gubareva, L.V., et al. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother. 50 (2006), 1470–1479.
92. 92 Zhirnov, O.P., Matrosovich, T.Y., Matrosovich, M.N., Klenk, H.D., Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemother. 21 (2011), 169–174.
93. 93 Ovcharenko, A.V., Zhirnov, O.P., Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res. 23 (1994), 107–118.
94. 94 Meyer, D., Sielaff, F., Hammami, M., Bottcher-Friebertshauser, E., Garten, W., Steinmetzer, T., Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem J. 452 (2013), 331–343.
95. 95 Razinkov, V.I., Melikyan, G.B., Epand, R.M., Epand, R.F., Cohen, F.S., Effects of spontaneous bilayer curvature on influenza virus-mediated fusion pores. J Gen Physiol. 112 (1998), 409–422.
96. 96 Harada, S., The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope. Biochem J. 392:Pt 1 (2005), 191–199.
97. 97 Wolkerstorfer, A., Kurz, H., Bachhofner, N., Szolar, O.H., Glycyrrhizin inhibits influenza A virus uptake into the cell. Antiviral Res. 83 (2009), 171–178.
98. 98 Wolf, M.C., Freiberg, A.N., Zhang, T., Akyol-Ataman, Z., Grock, A., Hong, P.W., et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 107 (2010), 3157–3162.
99. 99 Guinea, R., Carrasco, L., Requirement for vacuolar proton-ATPase activity during entry of influenza virus into cells. J Virol. 69 (1995), 2306–2312.
100. 100 Ochiai, H., Sakai, S., Hirabayashi, T., Shimizu, Y., Terasawa, K., Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antiviral Res. 27 (1995), 425–430.
101. 101 Muller, K.H., Kainov, D.E., El Bakkouri, K., Saelens, X., de Brabander, J.K., Kittel, C., et al. The proton translocation domain of cellular vacuolar ATPase provides a target for the treatment of influenza A virus infections. Br J Pharmacol. 164 (2011), 344–357.
102. 102 Wang, X., Hinson, E.R., Cresswell, P., The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. Cell Host Microbe. 2 (2007), 96–105.
103. 103 Naito, T., Momose, F., Kawaguchi, A., Nagata, K., Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. J Virol. 81 (2007), 1339–1349.
104. 104 Chase, G., Deng, T., Fodor, E., Leung, B.W., Mayer, D., Schwemmle, M., et al. Hsp90 inhibitors reduce influenza virus replication in cell culture. Virology. 377 (2008), 431–439.
105. 105 Streeter, D.G., Witkowski, J.T., Khare, G.P., Sidwell, R.W., Bauer, R.J., Robins, R.K., et al. Mechanism of action of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci U S A. 70 (1973), 1174–1178.
106. 106 Stephen, E.L., Walker, J.S., Dominik, J.W., Young, H.W., Berendt, R.F., Aerosol therapy of influenza infections of mice and primates with rimantadine, ribavirin, and related compounds. Ann N Y Acad Sci. 284 (1977), 264–271.
107. 107 Cohen, A., Togo, Y., Khakoo, R., Waldman, R., Sigel, M., Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis. 133:Suppl (1976), A114–A120.
108. 108 Rodriguez, W.J., Hall, C.B., Welliver, R., Simoes, E.A., Ryan, M.E., Stutman, H., et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: A double-blind, multicenter, placebo-controlled trial. J Pediatr. 125 (1994), 129–135.
109. 109 Perwitasari, O., Johnson, S., Yan, X., Howerth, E., Shacham, S., Landesman, Y., et al. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza A virus replication in vitro and in vivo. J Virol. 88 (2014), 10228–10243.
110. 110 Rossignol, J.F., La Frazia, S., Chiappa, L., Ciucci, A., Santoro, M.G., Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 284 (2009), 29798–29808.
111. 111 Haffizulla, J., Hartman, A., Hoppers, M., Resnick, H., Samudrala, S., Ginocchio, C., et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: A double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 14 (2014), 609–618.
112. 112 Pleschka, S., Wolff, T., Ehrhardt, C., Hobom, G., Planz, O., Rapp, U.R., et al. Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade. Nat Cell Biol. 3 (2001), 301–305.
113. 113 Ludwig, S., Wolff, T., Ehrhardt, C., Wurzer, W.J., Reinhardt, J., Planz, O., et al. MEK inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS Lett. 561 (2004), 37–43.
114. 114 Droebner, K., Pleschka, S., Ludwig, S., Planz, O., Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Res. 92 (2011), 195–203.
115. 115 Haasbach, E., Hartmayer, C., Planz, O., Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res. 98 (2013), 319–324.
116. 116 Wurzer, W.J., Ehrhardt, C., Pleschka, S., Berberich-Siebelt, F., Wolff, T., Walczak, H., et al. NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J Biol Chem. 279 (2004), 30931–30937.
117. 117 Nimmerjahn, F., Dudziak, D., Dirmeier, U., Hobom, G., Riedel, A., Schlee, M., et al. Active NF-kappaB signalling is a prerequisite for influenza virus infection. J Gen Virol. 85:Pt 8 (2004), 2347–2356.
118. 118 Mazur, I., Wurzer, W.J., Ehrhardt, C., Pleschka, S., Puthavathana, P., Silberzahn, T., et al. Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity. Cell Microbiol. 9 (2007), 1683–1694.
119. 119 Dodson, A.W., Taylor, T.J., Knipe, D.M., Coen, D.M., Inhibitors of the sodium potassium ATPase that impair herpes simplex virus replication identified via a chemical screening approach. Virology. 366 (2007), 340–348.
120. 120 Kapoor, A., Cai, H., Forman, M., He, R., Shamay, M., Arav-Boger, R., Human cytomegalovirus inhibition by cardiac glycosides: Evidence for involvement of the HERG gene. Antimicrob Agents Chemother. 56 (2012), 4891–4899.
121. 121 García-Dorival, I., Wu, W., Dowall, S., Armstrong, S., Touzelet, O., Wastling, J., et al. Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host-cell protein function. J Proteome Res. 13 (2014), 5120–5135.
122. 122 Burkard, C., Verheije, M.H., Haagmans, B.L., van Kuppeveld, F.J., Rottier, P.J., Bosch, B.J., et al. ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. J Virol. 89 (2015), 4434–4448.
123. 123 Thete, D., Danthi, P., Conformational changes required for reovirus cell entry are sensitive to pH. Virology. 483 (2015), 291–301.
124. 124 Deng, L., Dai, P., Ciro, A., Smee, D.F., Djaballah, H., Shuman, S., Identification of novel antipoxviral agents: Mitoxantrone inhibits vaccinia virus replication by blocking virion assembly. J Virology. 81 (2007), 13392–13402.
125. 125 Hoffmann, H.H., Palese, P., Shaw, M.L., Modulation of influenza virus replication by alteration of sodium ion transport and protein kinase C activity. Antiviral Res. 80 (2008), 124–134.
126. 126 Katzen, J., Hurtado, J., Lecuona, E., Sznajder, J.I., The cardioactive glycoside ouabain inhibits influenza A viral replication. Am J Respir Crit Care Med, 189, 2014 Abstract A2733.